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Nuclear receptors (NRs) are transcription factors whose activity is modulated by ligand binding.These
receptors are at the core of complex signaling pathways and act as integrators of many cellular signals. In
the last decade our understanding of NRs has greatly evolved. In particular, regulation of NR subcellular
dynamics has emerged as central to their activity. Research on the subcellular distribution of the thyroid
hormone receptor (TR) has revealed new dimensions in the complexity of NR regulation, and points to the
possibility that NR mislocalization plays a key role in oncogenesis. For many years,TR was thought to reside
exclusively in the nucleus. It is now known that TR is a dynamic protein that shuttles between the nucleus
and cytoplasm.TR is localized to the nucleus in a phosphorylated form, suggesting that compartment-specific
phosphorylation mediates cross-talk between multiple cell signaling pathways.The oncoprotein v-ErbA, a
viral-derived dominant negative variant of TR is actively exported to the cytoplasm by the CRM1 export
receptor. Strikingly, the oncoprotein causes mislocalization of cellular TR and some of its coactivators by
direct interaction. Here, we offer some perspectives on the role of subcellular trafficking in the oncogenic
conversion of TR, and propose a new model for oncoprotein dominant negative activity.
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Introduction
Members of the nuclear receptor (NR) superfamily are
ligand-regulated transcription factors that play crucial
roles in cell growth, differentiation, and proliferation. After
translation in the cytoplasm, NRs must enter the nucleus
to carry out their functions. In recent years, there has
been a tremendous increase in our mechanistic
understanding of the intricacies of subcellular trafficking
of NRs.The classical “two-step” model in which
cytoplasmic receptors, following hormone binding, acquire
the capacity to import into the nucleus and bind DNA, has
undergone a dramatic evolution that helped define two
classes of nuclear receptors. For class one receptors,
the ligand acts as a switch that allows their nuclear import,
while class two receptors are constitutively nuclear at
steady state. Moreover, the intranuclear mobility of NRs
and their interactions with target genes is much more
dynamic than originally envisioned [McNally et al., 2000].
Particularly striking is the shift in our view of the
intracellular mobility of the thyroid hormone receptor α 1
(TRα), a class two receptor.
The dual role of TRα, which can modulate transcription
whether it is bound to thyroid hormone (T3) or not [Nagl
et al., 1995], was long assumed to imply constitutive
nuclear localization.This dogma was overturned by the
discovery that, although TRα accumulates in the nucleus
at steady state, the receptor shuttles rapidly between the
cytoplasm and the nucleus [Bunn et al., 2001]. Although
the normal function of receptor nucleocytoplasmic
shuttling remains unclear, this capacity for bidirectional
transport between cellular compartments could represent
an Achilles heel for the receptor by allowing its
mislocalization.We propose that cytoplasmic
mislocalization of TRα by dominant negative variants may
contribute to the progression of some forms of cancer
[Bonamy et al., 2005].
Shuttling of TRα – sampling of signaling
pathways?
The functional significance of TRα shuttling remains
elusive, but could reflect a process that is cell-type
specific and/or dependent on the cellular environment.
Shuttling of TRα may serve to mediate receptor cross-talk
signaling pathways between cellular compartments, or
may play a role in receptor turnover via the
ubiquitin-proteasome degradation pathway [Dace et al.,
2000; Kenessey and Ojamaa, 2005]. However, it is not
clear from these studies whether T3-mediated
degradation of ubiquitinylated TR occurs in the nucleus
or in the cytoplasm. Phosphorylation events are thought
to play an important role in receptor action at the
molecular level [Nicoll et al., 2003]. For instance, changes
in TR phosphorylation state alters its transcriptional
activity [Jones et al., 1994]. Furthermore, phosphorylation
of TRα and TRβ by mitogen–activated protein kinase
appears to increase TR stability by shielding the receptor
from proteasome degradation [Chen et al., 2003].The
additional checkpoint in receptor control of T3-responsive
gene expression provided by shuttling potentially could
be regulated by compartment-specific phosphorylation.
A phosphorylated form of TRα is present in the nucleus,
whereas unphosphorylated TRα remains cytoplasmic
[Nicoll et al., 2003]. Changes in the phosphorylation state
of TRα occur rapidly and phosphorylation appears to take
place in the nucleus.These findings point to the
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be linked to NR trafficking. However, the specific role of
TR shuttling, whether it is to integrate messages in the
cytoplasm or mediate cytoplasmic degradation, remains
to be determined.
Altered nuclear export of dominant
negative variants of TR
Dominant negative mutants of TR with defects in DNA
binding and transactivation accumulate in the cytoplasm
at steady state, illustrating that even single amino acid
changes in functional domains may lead to a dramatic
shift in the subcellular distribution of TR [Bunn et al.,
2001]. One such variant, the oncoprotein v-ErbA, is found
in the nucleus, but is mainly cytoplasmic at steady state.
v-ErbA is an oncogenic derivative of TRα (c-ErbA) carried
by the avian erythroblastosis virus (AEV). It contains
several alterations including the fusion of a portion of AEV
Gag to its N-terminus, N- and C-terminal deletions, and
13 amino acid substitutions. Although v-ErbA has retained
the capacity to bind corepressors, it has lost
hormone-binding and transactivation activity and has
altered DNA binding specificity [Urnov et al., 2000].The
oncoprotein interferes with the action of TRα in
mammalian and avian cancer cells. Like TRα, v-ErbA is
also a shuttling protein. v-ErbA follows a CRM1-mediated
export pathway that is sensitive to leptomycin B, a
CRM1-specific inhibitor [Bunn et al., 2001; DeLong et al.,
2004]. CRM1 is a highly conserved member of the
importin-β family and a receptor for leucine-rich nuclear
export sequences (NESs). Study of the subcellular
trafficking of green fluorescent protein (GFP)-tagged
mutant and chimeric v-ErbA proteins in mammalian cells
showed that a NES resides within a 70 amino acid domain
in the C-terminal portion of the p10 region of Gag, and in
vitro binding assays demonstrated that Gag interacts
directly with CRM1.Thus, the fusion of the viral gag
sequence with c-erbA was a crucial step in the activation
of the oncoprotein.
The role of various export receptors in carrying NRs from
the nucleus to the cytoplasm has been controversial.
Several lines of evidence implicate calreticulin as the
mediator of NR nuclear export, while other studies
suggest a CRM1-mediated pathway [Shank and Paschal,
2005]. In heterokaryon assays, in which the cell fusion
step may induce release of calreticulin from the
endoplasmic reticulum [Shank and Paschal, 2005], rapid
TRα and TRβ1 shuttling is CRM1-independent [Bunn et
al., 2001; DeLong et al., 2004]. Heterokaryon assays
conducted with v-ErbA show that the oncoprotein has
lost the ability to use this alternate, calreticulin-mediated
export pathway [Bunn et al., 2001; DeLong et al., 2004].
Subcellular mislocalization of the
oncoprotein v-ErbA
The growth-promoting properties of v-ErbA have
traditionally been linked to dominant repression of the
anti-mitogenic roles of TR and the retinoic acid receptor
(RAR). However, another aspect of v-ErbA’s role in cell
cycle induction is its ability to induce ultrastructural
changes characteristic of early and intermediate events
of meiotic maturation in Xenopus oocytes [Nagl et al.,
1997]. v-ErbA-induced maturation events, which are not
mediated by dominant repression of endogenous TR,
occur without activation of the
cAMP/maturation-promoting factor signal pathway, and
arrest prior to meiotic spindle formation.These studies
suggest that v-ErbA, acting as a transcriptional activator,
can contribute to cell cycle reentry by interference with
regulatory pathways distinct from those involving TR. A
portion of v-ErbA expressed in Xenopus oocytes localizes
to the cytoplasmic fibrils of the nuclear pore complexes
[Nagl et al., 1997], thus suggesting the interesting
possibility that in addition to its intranuclear function,
v-ErbA may modulate nucleocytoplasmic transport.
The acquisition of altered nuclear export capabilities
contributes to the oncogenic properties of v-ErbA by
adding yet another level of dominant negative activity.
v-ErbA oncogenic activity has long been attributed to
competition with TRα for T3-responsive DNA elements
and/or auxiliary factors involved in the transcriptional
regulation of T3-responsive genes. However, competition
models do not address the altered subcellular localization
of v-ErbA as a mode of oncogenic action. In situ
protein-protein interaction assays, and colocalization
studies in transiently transfected cells indicate that v-ErbA
dimerizes with TRα and the retinoid X receptor (RXR)
and sequesters a significant fraction of the two NRs in
the cytoplasm [Bonamy et al., 2005]. Notably, recruitment
of TRα to the cytoplasm by v-ErbA can be partially
reversed in the presence of ligand, and when chromatin
is disrupted by the histone deacetylase inhibitor
trichostatin A.T3 favors TR heterodimer formation with
RXR, which would prevent its recruitment by v-ErbA; while
trichostatin A decondenses the chromatin, which
increases the number of response elements accessible
to TR and enhances its nuclear retention.
A new model for dominant negative
action of the oncoprotein v-ErbA
Our current model for the dominant negative activity of
v-ErbA highlights the importance of its aberrant
mislocalization of NRs in oncogenesis (Figure 1). In the
absence of v-ErbA, unliganded and liganded TRα, along
with RXR, repress or enhance the transcription of specific
genes. In the presence of the oncoprotein, the normal
transcriptional activity of TRα and RXR is antagonized
by competition with v-ErbA for DNA response elements
and/or cofactors, and mislocalization of TRα and RXR to
the cytoplasm. Because unliganded TRα is more sensitive
to mislocalization, in the absence of T3 v-ErbA dominant
negative activity may be mediated to a greater degree by
cytoplasmic mislocalization.This mislocalization is most
likely due to the CRM1-mediated nuclear export of TRα
and RXR, which are “piggybacked” to the cytoplasm by
v-ErbA after formation of the dimers in the nucleus, and
to the anchoring of these receptors by v-ErbA in the
cytoplasm.
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actively imported into the nucleus through the nuclear pore complexes (NPC). In the nucleus, TR is phosphorylated (red circle), which may serve to
modify its activity and enhance nuclear retention. In the nucleus, TR and RXR bind to DNA response elements as homodimers or heterodimers, and
modulate transcription of T3-responsive genes (green arrows). Although TR and RXR are shuttling proteins, the balance between nuclear import,
nuclear retention, and nuclear export is such that these two receptors are almost entirely localized in the nucleus at steady state.Their nuclear export
may be mediated by calreticulin, but this requires further evaluation. In contrast, in the presence of the oncoprotein v-ErbA (red symbol) (bottom), RXR
and TR either dimerize with v-ErbA on some response elements, or are blocked from DNA binding sites by competition with v-ErbA monomers. In both
cases, this interferes with the normal transcriptional activity of T3-responsive genes (red crossed arrows). In addition, a significant fraction of RXR and
TR exits the nucleus “piggyback” style by a CRM1-dependent pathway in association with v-ErbA and its viral NES.TR and RXR may be actively
anchored in the cytoplasm by the retroviral Gag moiety of v-ErbA.The mislocalization of TR, RXR and possibly other coactivators by v-ErbA blocks
these transcription factors from their normal function in the nucleus.Together, all these mechanisms contribute to cellular transformation by v-ErbA,
resulting in cancer.
Retroviruses can acquire host DNA sequences via
conserved mechanisms that result in the fusion of the
cellular proto-oncogene to a sequence encoding
variable-sized N-terminal fragments of the Gag
polyprotein. Because Gag is a cytoplasmic protein, fusion
to nuclear proteins may often result in the ectopic
expression of a fusion protein localized to the cytoplasm.
This raises the interesting possibility that viral oncogenes
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tumorigenesis in part via mislocalization of different
cellular factors.Whether the example of v-ErbA
represents a widespread mechanism or not remains to
be determined.
Cancer and mislocalization of regulatory
proteins
Signal-mediated nuclear localization of transcription
factors can act as a regulatory pathway to control
transcription.Thus, it is not surprising that disruption of
the critical balance between nuclear import, nuclear
retention, and nuclear export of transcription regulatory
proteins is associated with cancer and other diseases
[for review, Kau et al., 2004]. For example, mislocalization
of INI1/nSNF5 blocks its normal tumor suppression
function [Craig et al., 2002], the tumor suppressor p53 is
abnormally exported from the nucleus and/or sequestered
in the cytoplasm in some transformed cells [Stommel et
al., 1999]]. In addition, ectopic expression of the hepatitis
B virus X protein sequesters CRM1 in the cytoplasm,
suggesting that inactivation of the CRM1-mediated
pathway may be an early step during viral
hepatitis-mediated liver carcinogenesis [Forgues et al.,
2001]. Moreover, a recent report suggests that the
hepatitis C virus core protein modulates the retinoid
signaling pathway by sequestering Sp110b, a corepressor
of RARα [Watashi et al., 2003]. In support of this model,
Sp110b is mislocalized by the core protein to the
perinuclear region in situ. In addition, the core protein
and Sp110b were both enriched in the microsomal
membrane fraction after biochemical extraction,
suggesting mislocalization to the endoplasmic reticulum.
Other studies have also implicated mislocalization of
regulatory proteins in the progression of cancer. For
example, cytoplasmic mislocalization of mutant BRCA1
is associated with breast cancer [Rodriguez et al., 2004].
In acute promyelocytic leukemia cells that express
chimeric RARα fusion proteins, normal RXRα aberrantly
colocalizes with the chimeric protein, and shows
decreased intranuclear mobility [Dong et al., 2004].
Further, functional inactivation of the tumor suppressor
p27 (kip1) in human thyroid cancers occurs either through
loss of expression or through phosphorylation-dependent
cytoplasmic sequestration [Motti et al., 2005], and loss
of tumor suppressor RUNX3 expression is causally
related to gastric cancer and linked to its impaired nuclear
localization [Ito et al., 2005]. Finally, a human prostate
cancer was linked to a mutant of the androgen receptor,
which is aberrantly localized in nuclear foci and
subsequently mislocalizes SRC-1 [Nazareth et al., 1999].
Concluding remarks
In summary, oncogenic conversion of TRα into v-ErbA
not only involves changes in DNA binding specificity and
ligand binding properties, but also the acquisition of
altered nuclear export capabilities and subcellular
localization [Bonamy et al., 2005]. Other dominant
negative variants of TR may be involved in human cancer
[Gonzalez-Sancho et al., 2003]. For instance, point
mutations in TRα have been linked to pituitary tumors
[McCabe et al., 1999], to thyroid papillary cancer
[Puzianowska-Kuznicka et al., 2002] and to gastric cancer
[Wang et al., 2002].Thus, it would be interesting to
assess the localization of TR variants in cancer cells to
determine if there is an altered distribution of mutant and
wild-type receptors.
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